Inactivation of Antibiotic Resistance in Clinical Isolates of Pathogenic Enterobacteriaceae

致病性肠杆菌科临床分离株抗生素耐药性的灭活

• 批准号: 133343
• 金额: $ 13.21万
• 依托单位: NEMESIS BIOSCIENCE LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=133343
• 关键词: Inactivation; Antibiotic; Resistance; Clinical; Isolates

Nemesis Bioscience has invented, developed and protected a family of novel biological therapeutic agents that inactivate resistance to antibiotics, so allowing well-established and safe antibiotics to be effective again. Resurrecting antibiotic susceptibility eliminates the threat of ‘super bugs’ and ensures current and newly developed antibiotics retain efficacy over the long-term. The company has proven that its “Nemesis Symbiotics” convert antimicrobial resistant (AMR) bacteria to antibiotic sensitivity and also prevent bacteria from acquiring AMR – presenting the possibility of protecting patients pre-operatively, or even pre-admission, to lower the risks of subsequent AMR infection. In the current study the company will complete experimental work to validate its technology in pathogenic bacteria isolated from clinical infections and demonstrate that its Symbiotic technology can have real-world application for the treatment and prevention of infections with antibiotic resistant bacteria. The company’s products will have significantly shorter development times than existing antimicrobials. To date the company has raised funds from its founders, Angel investors, the Rainbow Seed Fund and from Finance Wales. The company won the King’s College, Cambridge Entrepreneurship Award for 2014.

Nemesis Bioscience发明、开发和保护了一系列新型生物治疗剂，这些治疗剂可以消除抗生素的耐药性，从而使已经确立的安全抗生素再次有效。恢复抗生素敏感性消除了“超级细菌”的威胁，并确保目前和新开发的抗生素长期保持疗效。该公司已经证明，其“Nemesis Symbiotics”将抗菌素耐药性（AMR）细菌转化为抗生素敏感性，并防止细菌获得AMR -提供了在术前甚至入院前保护患者的可能性，以降低随后AMR感染的风险。在目前的研究中，该公司将完成实验工作，以验证其在临床感染中分离的致病菌中的技术，并证明其共生技术可以在现实世界中应用于治疗和预防抗生素耐药菌感染。该公司的产品将比现有抗菌剂的开发时间短得多。迄今为止，该公司已从其创始人、天使投资者、彩虹种子基金和威尔士金融公司筹集了资金。该公司获得了2014年剑桥国王学院创业奖。